Abstract
Non-alcoholic fatty liver disease (NAFLD) is increasingly common due to the rising prevalence of obesity in both children and adults. It is associated with metabolic risk factors such as diabetes mellitus, dyslipidaemia and hypertension, and is associated with increased mortality both from cardiovascular-related and liver-related deaths. Identification of those individuals with significant inflammation and fibrosis is a critical part of the patient pathway. Current treatments for NAFLD include weight loss from lifestyle modification or bariatric surgery, management of underlying metabolic risk factors and for those with end stage liver disease, liver transplantation.
Original language | English |
---|---|
Pages (from-to) | 186-190 |
Number of pages | 5 |
Journal | Clinical Medicine |
Volume | 15 |
Issue number | 2 |
DOIs | |
Publication status | Published - Apr 2015 |